OrthoPediatrics (NASDAQ:KIDS) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

OrthoPediatrics (NASDAQ:KIDS) announced its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03, FiscalAI reports. The company had revenue of $61.61 million for the quarter, compared to analysts’ expectations of $61.27 million. OrthoPediatrics had a negative return on equity of 6.86% and a negative net margin of 20.06%.

Here are the key takeaways from OrthoPediatrics’ conference call:

• Financials & guidance: Q4 revenue was $61.6M (+17% YoY) and FY2025 revenue grew 15% with adjusted EBITDA and free cash flow materially improved (Q4 FCF of $10M); management reiterated 2026 guidance of $262–266M revenue, ~ $25M adjusted EBITDA and full‑year free‑cash‑flow breakeven.
• Product “super cycle”: Management launched a multi‑year innovation wave (3P Hip, VerteGlide, eLLi with first‑in‑human expected late 2026, Halo Gravity Traction, Playbook) and expects these high‑value products to drive share gains and margin expansion.
• OPSB bracing momentum: Clinic expansion is ahead of schedule, same‑store sales are strong, and multiple new brace launches (DF2 expansions, PD Hip Brace portfolio and adjunct TrakFix products) are positioned to support revenue and profitability.
• International & regulatory progress: OUS revenue rebounded (+33% Q4), EU MDR approvals and the Folomed distributor acquisition in Brazil are expected to improve European and LatAm penetration, ordering stability and cash collection.
• R&D cadence and pipeline risk: Reported R&D spending was lower in 2025 (management attributes this to timing), and while leadership says the pipeline remains strong, uneven R&D timing and future spend variability could introduce execution risk.

OrthoPediatrics Trading Up 6.4%

Shares of NASDAQ KIDS traded up $1.07 during trading hours on Thursday, hitting $17.79. The company’s stock had a trading volume of 150,380 shares, compared to its average volume of 111,435. OrthoPediatrics has a 12 month low of $15.28 and a 12 month high of $26.40. The stock has a market cap of $446.17 million, a price-to-earnings ratio of -9.12 and a beta of 1.12. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.52 and a current ratio of 7.40. The business has a 50-day simple moving average of $17.60 and a 200-day simple moving average of $18.15.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on KIDS shares. Wall Street Zen cut shares of OrthoPediatrics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a report on Thursday, January 22nd. Needham & Company LLC lowered their price target on shares of OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a research note on Wednesday, October 29th. BTIG Research restated a “buy” rating and set a $23.00 price target on shares of OrthoPediatrics in a research report on Wednesday, October 29th. Finally, Canaccord Genuity Group started coverage on OrthoPediatrics in a research note on Wednesday, December 10th. They set a “buy” rating and a $24.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.89.

Institutional Investors Weigh In On OrthoPediatrics

Institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after buying an additional 645 shares during the period. Millennium Management LLC boosted its holdings in OrthoPediatrics by 55.3% in the first quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after acquiring an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in OrthoPediatrics by 112.3% in the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after acquiring an additional 106,041 shares in the last quarter. Jane Street Group LLC purchased a new position in OrthoPediatrics during the 1st quarter valued at $389,000. Finally, American Century Companies Inc. raised its holdings in OrthoPediatrics by 12.5% in the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock worth $741,000 after purchasing an additional 3,828 shares in the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.